Literature DB >> 19383972

The molecular basis of hepcidin-resistant hereditary hemochromatosis.

Augustine Fernandes1, Gloria C Preza, Yen Phung, Ivana De Domenico, Jerry Kaplan, Tomas Ganz, Elizabeta Nemeth.   

Abstract

The interaction between the hormone hepcidin and the iron exporter ferroportin (Fpn) regulates plasma iron concentrations. Hepcidin binds to Fpn and induces its internalization and degradation, resulting in decreased iron efflux from cells into plasma. Fpn mutations in N144, Y64N, and C326 residue cause autosomal dominant disease with parenchymal iron overload, apparently due to the resistance of mutant Fpn to hepcidin-mediated internalization. To define the mechanism of resistance, we generated human Fpn constructs bearing the pathogenic mutations. The mutants localized to the cell surface and exported iron normally, but were partially or completely resistant to hepcidin-mediated internalization and continued to export iron despite the presence of hepcidin. The primary defect with exofacial C326 substitutions was the loss of hepcidin binding, which resulted in the most severe phenotype. The thiol form of C326 was essential for interaction with hepcidin, suggesting that C326-SH homology is located in or near the binding site of hepcidin. In contrast, N144 and Y64 residues were not required for hepcidin binding, but their mutations impaired the subsequent internalization of the ligand-receptor complex. Our observations explain why the mutations in C326 Fpn residue produce a severe form of hemochromatosis with iron overload at an early age.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383972      PMCID: PMC2714214          DOI: 10.1182/blood-2008-03-146134

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features.

Authors:  Ronald L Sham; Pradyumna D Phatak; Carol West; Pauline Lee; Caroline Andrews; Ernest Beutler
Journal:  Blood Cells Mol Dis       Date:  2005 Mar-Apr       Impact factor: 3.039

2.  The molecular basis of ferroportin-linked hemochromatosis.

Authors:  Ivana De Domenico; Diane McVey Ward; Elizabeta Nemeth; Michael B Vaughn; Giovanni Musci; Tomas Ganz; Jerry Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-13       Impact factor: 11.205

3.  Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.

Authors:  Elizabeta Nemeth; Marie S Tuttle; Julie Powelson; Michael B Vaughn; Adriana Donovan; Diane McVey Ward; Tomas Ganz; Jerry Kaplan
Journal:  Science       Date:  2004-10-28       Impact factor: 47.728

4.  In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.

Authors:  Lisa M Schimanski; Hal Drakesmith; Alison T Merryweather-Clarke; Vip Viprakasit; Jon P Edwards; Emma Sweetland; Judy M Bastin; Diana Cowley; Yingyong Chinthammitr; Kathryn J H Robson; Alain R M Townsend
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

5.  A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient.

Authors:  K E Arden; D F Wallace; J L Dixon; L Summerville; J W Searle; G J Anderson; G A Ramm; L W Powell; V N Subramaniam
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

6.  Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis.

Authors:  C M Craven; J Alexander; M Eldridge; J P Kushner; S Bernstein; J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

Review 7.  The ferroportin disease.

Authors:  Antonello Pietrangelo
Journal:  Blood Cells Mol Dis       Date:  2004 Jan-Feb       Impact factor: 3.039

8.  Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis.

Authors:  Daniel F Wallace; Roslyn M Clark; Hugh A J Harley; V Nathan Subramaniam
Journal:  J Hepatol       Date:  2004-04       Impact factor: 25.083

9.  Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene.

Authors:  A Pietrangelo; G Montosi; A Totaro; C Garuti; D Conte; S Cassanelli; M Fraquelli; C Sardini; F Vasta; P Gasparini
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

10.  Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family.

Authors:  Sylvain R Rivard; Carmela Lanzara; Doria Grimard; Massimo Carella; Hervey Simard; Romina Ficarella; Raynald Simard; Adamo Pio D'Adamo; Marc De Braekeleer; Paolo Gasparini
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

View more
  56 in total

Review 1.  The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

Review 3.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

Review 4.  Mammalian iron metabolism and its control by iron regulatory proteins.

Authors:  Cole P Anderson; Macy Shen; Richard S Eisenstein; Elizabeth A Leibold
Journal:  Biochim Biophys Acta       Date:  2012-05-17

5.  Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo.

Authors:  Lei Wang; Bin Fang; Toshifumi Fujiwara; Kimberly Krager; Akshita Gorantla; Chaoyuan Li; Jian Q Feng; Michael L Jennings; Jian Zhou; Nukhet Aykin-Burns; Haibo Zhao
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

Review 6.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

Review 7.  Molecular mechanisms of normal iron homeostasis.

Authors:  An-Sheng Zhang; Caroline A Enns
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 9.  The role of hepcidin in iron metabolism.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Acta Haematol       Date:  2009-11-10       Impact factor: 2.195

10.  Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin.

Authors:  Sergei Nekhai; Min Xu; Altreisha Foster; Ishmael Kasvosve; Sharmin Diaz; Roberto F Machado; Oswaldo L Castro; Gregory J Kato; James G Taylor; Victor R Gordeuk
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.